Participant flow24

How many started, completed or left each group, period by period.

1 to 20 of 24

Period	Milestone	Group	Participants
Overall Study	STARTED	Semaglutide 0.1 mg	80
Overall Study	STARTED	Semaglutide 0.2 mg	78
Overall Study	STARTED	Semaglutide 0.4 mg	82
Overall Study	STARTED	Placebo	80
Overall Study	Full Analysis Set	Semaglutide 0.1 mg	80
Overall Study	Full Analysis Set	Semaglutide 0.2 mg	78
Overall Study	Full Analysis Set	Semaglutide 0.4 mg	82
Overall Study	Full Analysis Set	Placebo	80
Overall Study	Safety Analysis Set	Semaglutide 0.1 mg	80
Overall Study	Safety Analysis Set	Semaglutide 0.2 mg	78
Overall Study	Safety Analysis Set	Semaglutide 0.4 mg	81
Overall Study	Safety Analysis Set	Placebo	80
Overall Study	Exposed	Semaglutide 0.1 mg	80
Overall Study	Exposed	Semaglutide 0.2 mg	78
Overall Study	Exposed	Semaglutide 0.4 mg	81
Overall Study	Exposed	Placebo	80
Overall Study	COMPLETED	Semaglutide 0.1 mg	76
Overall Study	COMPLETED	Semaglutide 0.2 mg	72
Overall Study	COMPLETED	Semaglutide 0.4 mg	77
Overall Study	COMPLETED	Placebo	77

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02970942/flow